Table 1.

Relationship between the expression of miR-1269 and clinicopathological parameters in HCC

Clinicopathological Feature		n	miR-1269 relevant expression (2-ΔCq)
			Mean ± SD	t	P
Tissue	Adjacent non-cancerous liver	95	1.5518±0.7273	3.578	< 0.001
	HCC	95	1.9264±0.7160
Age	≥ 50	46	1.9070±0.7156	0.255	0.799
	< 50	49	1.9447±0.7232
Gender	male	75	1.8645±0.7315	1.646	0.103
	female	20	2.1585±0.6165
Differentiation	high	6	2.1183±0.8424	*F = 0.794	0.455
	moderate	60	1.9697±0.6880
	low	29	1.7972±0.7535
Size	< 5 cm	18	2.1050±0.9294	1.178	0.242
	≥ 5 cm	77	1.8847±0.6569
Tumor nodes	single	52	1.7937±0.6762	2.020	0.046
	multiple	43	2.0870±0.7375
Metastasis	Without metastasis	46	1.7667±0.6838	2.146	0.034
	With metastasis	49	2.0763±0.7199
Clinical TNM stage	I~II	22	1.6609±0.7819	2.016	0.047
	III~IV	73	2.0064±0.6804
Portal vein tumor embolus	-	63	1.8017±0.6475	2.444	0.016
	+	32	2.1719±0.7887
Vaso-invasion	-	59	1.7817±0.6803	2.598	0.011
	+	36	2.1636±0.7188
Tumor capsular infiltration	With complete capsule	45	1.6327±0.6334	4.100	< 0.001
	No capsule or infiltration	50	2.1908±0.6875
HCV	-	63	1.8694±0.6890	1.091	0.278
	+	32	2.0388±0.7650
HBV	-	17	2.0994±0.9718	0.853	0.404
	+	78	1.8887±0.6492
AFP	-	41	1.9029±0.7423	0.586	0.560
	+	38	1.9979±0.6847
Cirrhosis	-	50	1.8636±0.7643	0.901	0.370
	+	45	1.9962±0.6597
nm23	-	20	1.8110±0.8699	0.810	0.420
	+	75	1.9572±0.6725
MTDH	-	131	1.5931±0.6876	3.127	0.002
	+	47	1.9694±0.7357
P53	-	40	1.8470±0.7444	0.921	0.359
	+	55	1.9842±0.6958
P21	-	62	1.8647±0.7382	1.154	0.251
	+	33	2.0424±0.6677
VEGF	-	25	1.8248±0.8502	0.735	0.467
	+	70	1.9627±0.6647
Ki-67 LI	Low	47	1.8670±0.6835	0.799	0.427
	High	48	1.9846±0.7490
MVD	Low	47	1.9555±0.7505	0.390	0.697
	High	48	1.8979±0.6872

^*ANOVA was performed to analyze the difference of miR-1269 among differentiation grading.